Acyclovir in first attacks of genital herpes and prevention of recurrences. 1986

A Mindel, and I V Weller, and A Faherty, and S Sutherland, and A P Fiddian, and M W Adler

Sixty women patients experiencing a first attack of genital herpes were randomly treated with either oral acyclovir for 42 days or oral acyclovir for five days followed by placebo for 37 days. The median time to the first recurrence in patients receiving acyclovir for 42 days was 66.5 days compared with 24 days in those who received acyclovir for only five days (p less than 0.0001). This significant difference, however, was only observed for the treatment period. The frequency of recurrences was also reduced during the period of treatment in those who received prolonged treatment. During the subsequent follow up period, however, patients in both groups had a similar frequency of recurrences. Patients with infections due to herpes simplex virus type I (HSV I) had a significantly longer time to the first recurrence (p less than 0.001) and fewer recurrences (p less than 0.001) than those infected with HSV II, irrespective of treatment.

UI MeSH Term Description Entries
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females
D006558 Herpes Genitalis Infection of the genitals (GENITALIA) with HERPES SIMPLEX VIRUS in either the males or the females. Genital Herpes,Herpes Simplex, Genital,Herpes Simplex Virus Genital Infection,Genital Herpes Simplex,Herpes, Genital
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000212 Acyclovir A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes. Acycloguanosine,9-((2-Hydroxyethoxy)methyl)guanine,Aci-Sanorania,Acic,Aciclobeta,Aciclostad,Aciclovir,Aciclovir Alonga,Aciclovir-Sanorania,Acifur,Acipen Solutab,Acivir,Activir,Acyclo-V,Acyclovir Sodium,Antiherpes Creme,Avirax,Cicloferon,Clonorax,Cusiviral,Genvir,Herpetad,Herpofug,Herpotern,Herpoviric,Isavir,Laciken,Mapox,Maynar,Milavir,Opthavir,Supraviran,Viclovir,Vipral,Virax-Puren,Virherpes,Virmen,Virolex,Virupos,Virzin,Wellcome-248U,Zoliparin,Zovirax,Zyclir,aciclovir von ct,Aci Sanorania,Aciclovir Sanorania,Acyclo V,Alonga, Aciclovir,Sodium, Acyclovir,Solutab, Acipen,Virax Puren,ViraxPuren,Wellcome 248U,Wellcome248U
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

A Mindel, and I V Weller, and A Faherty, and S Sutherland, and A P Fiddian, and M W Adler
October 1984, Antiviral research,
A Mindel, and I V Weller, and A Faherty, and S Sutherland, and A P Fiddian, and M W Adler
January 1989, Obstetrics and gynecology,
A Mindel, and I V Weller, and A Faherty, and S Sutherland, and A P Fiddian, and M W Adler
April 1988, Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases,
A Mindel, and I V Weller, and A Faherty, and S Sutherland, and A P Fiddian, and M W Adler
May 1991, The Journal of antimicrobial chemotherapy,
A Mindel, and I V Weller, and A Faherty, and S Sutherland, and A P Fiddian, and M W Adler
January 2001, Infectious diseases in obstetrics and gynecology,
A Mindel, and I V Weller, and A Faherty, and S Sutherland, and A P Fiddian, and M W Adler
May 1987, Lancet (London, England),
A Mindel, and I V Weller, and A Faherty, and S Sutherland, and A P Fiddian, and M W Adler
November 1982, The New England journal of medicine,
A Mindel, and I V Weller, and A Faherty, and S Sutherland, and A P Fiddian, and M W Adler
May 2020, Marine drugs,
A Mindel, and I V Weller, and A Faherty, and S Sutherland, and A P Fiddian, and M W Adler
December 1983, Antiviral research,
A Mindel, and I V Weller, and A Faherty, and S Sutherland, and A P Fiddian, and M W Adler
March 2000, JAMA,
Copied contents to your clipboard!